Jiangsu Recbio Technology Co., Ltd (HKG: 2179) and Shanghai Rongsheng Biotech Co., Ltd have announced a strategic partnership aimed at the joint development of innovative adjuvant vaccine technologies. The collaborative project, headquartered in Shanghai, will see Recbio contribute its independently developed new adjuvant based on their proprietary adjuvant technology platform. Concurrently, Rongsheng Biotech will bring to the table its independently designed viral antigen.
Rongsheng anticipates that the integration of Recbio’s adjuvant technology with its existing portfolio of viral and bacterial vaccines will significantly enhance immunogenicity, a critical factor in vaccine efficacy. While the companies have not disclosed further details of the agreement, this partnership highlights a concerted effort to advance vaccine development through synergistic technological collaboration.- Flcube.com
